Randomized trial · people

Ecnoglutide: 13.2% weight loss at 40 weeks in the 2.4 mg arm

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a large placebo-controlled trial, weekly ecnoglutide led to more weight loss at higher doses over 40 weeks, and most people had side effects, mainly mild-to-moderate stomach and gut problems.

Kind
Randomized trial
Studied in
People
Number studied
664
Published
2025
Journal
Lancet Diabetes Endocrinol

What they tested

The team tested whether once-weekly ecnoglutide shots lower body weight more than placebo, a dummy shot, in adults with overweight or obesity, and how safe the drug is.

How the study was done

A randomized, double-blind, placebo-controlled phase 3 trial at 36 centers in China in 664 adults aged 18-75 with overweight or obesity and no diabetes. Participants got weekly shots of ecnoglutide 1.2, 1.8 or 2.4 mg, or placebo, and were measured at week 40.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking ecnoglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 40, average body weight changed by -9.1% in the 1.2 mg arm, -10.9% in the 1.8 mg arm and -13.2% in the 2.4 mg arm, compared with 0.1% on placebo. Compared with placebo, the differences were -9.2%, -11.1% and -13.3% (all p<0.0001). At least 5% of body weight was lost by 77%, 84% and 87% of people on the three doses, versus 16% on placebo. Side effects showed up in 93% of each ecnoglutide group and 84% of the placebo group, mostly mild-to-moderate stomach and gut problems, and some people on ecnoglutide stopped treatment because of them.

What it doesn’t show

The trial included only Chinese adults without diabetes and ran for 40 weeks, so it does not show longer-term results or results in other groups. It was funded by Hangzhou Sciwind Biosciences.

The paper

Ji et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025.

The compound

More studies on Ecnoglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking ecnoglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo